Table 1.
Clinical characteristics of study subjects and baseline therapy.
| Parameter | Mean or number | s.d. |
|---|---|---|
| Total number | 16 | |
| Male/female | 13/3 | |
| Age (years) | 68 | 10 |
| DBP (mm Hg) | 71 | 10 |
| SBP (mm Hg) | 126 | 18 |
| Heart rate (beats min−1) | 66 | 13 |
| 24 h SDNN | 142 | 57 |
| 24 h SDANN | 121 | 44 |
| 24 h SDNNi | 69 | 56 |
| 24 h rMSSD | 45 | 36 |
| Triangular index | 34 | 15 |
| 24 h MHR (beats min−1) | 69 | 12 |
| Weight (kg) | 74 | 13 |
| BMI | 30 | 5 |
| Plasma urea (mmol l−1) | 6 | 2 |
| Plasma creatinine (µmol l−1) | 144 | 46 |
| Plasma urate (mmol l−1) | 0.52 | 0.11 |
| Plasma potassium (mmol l−1) | 4 | 0.5 |
| Plasma sodium (mmol l−1) | 136 | 2 |
| Plasma ACE (U l−1) | 9 | 2 |
| Plasma BNP (pg ml−1) | 52 | 47 |
| Urinary urate | 0.62 | |
| NYHA class | ||
| II/III/IV | 9/5/2 | |
| LVEF% | 26 | 7 |
| Previous MI | 14 | |
| Dilated cardiomyopathy | 2 | |
| Baseline therapy | ||
| Frusemide (mg day−1) | 73 (16) | 59 |
| ACEI (mean dose mg enalapril equivalent day−1) | 17 (16) | 12 |
| Nitrate (n =) mg day−1 | ||
| Digoxin (n=) µg day−1 | 208 (6) | 102 |
| Aspririn (n=) mg day−1 | 152 (12) | 100 |
DBP, diastolic blood pressure; SBP, systolic blood pressure; BMI, body mass index; ACEI, angiotensin converting enzyme inhibitor; MHR, mean heart rate.
Figures in parentheses indicate number of patients.